ImageneBio Incorporation Aktie
Marktkapitalisierung
46,51 Mio. $
46,51 Mio. $
Streubesitz
40,58%
KGV
-1,7
Index-Zuordnung
-
ImageneBio, Inc. Unternehmensprofil
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. im Juli 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Vorstand
Dr. Kristin Yarema Ph.D.
CEO & Direktor
Frau Yanina Grant-Huerta
CFO, leitender Finanzbeamter & Leitender Rechnungsführer
Dr. Kurinji Pandiyan Ph.D.
Chief Strategy & Betriebsleiter
Frau Renuka Sivendran Ph.D.
Technischer Leiter
Herr Matt Robbins, J.D.
Chefsyndikus
Aktionärsstruktur
54,495%
Institutionelle Aktionäre
51,299%
Freefloat
0%
Individuelle Aktionäre
Unternehmenstermine
Stammdaten
| Nennwert/Aktie | - |
| Land | USA |
| Währung | USD |
| Branche | Biotechnologie |
| Aktientyp | - |
| Sektor | Gesundheit |
| Gattung | - |
Quelle: Leeway